Følg
Cecilie Johannessen Landmark
Cecilie Johannessen Landmark
Professor of Pharmacology, Oslo Metropolitan University/National Center for Epilepsy/Dept Pharm
Verifisert e-postadresse på oslomet.no
Tittel
Sitert av
Sitert av
År
Mechanisms of action of valproate: a commentatory
CU Johannessen
Neurochemistry international 37 (2-3), 103-110, 2000
4892000
Valproate: past, present, and future
CU Johannessen, SI Johannessen
CNS drug reviews 9 (2), 199-216, 2003
4662003
Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy
CJ Landmark
CNS drugs 22, 27-47, 2008
4602008
Antiepileptic drug interactions-principles and clinical implications
S I Johannessen, C Johannessen Landmark
Current neuropharmacology 8 (3), 254-267, 2010
4202010
Drug interactions involving the new second-and third-generation antiepileptic drugs
C Johannessen Landmark, PN Patsalos
Expert review of neurotherapeutics 10 (1), 119-140, 2010
3772010
Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications
T Tomson, CJ Landmark, D Battino
Epilepsia 54 (3), 405-414, 2013
2212013
Targets for antiepileptic drugs in the synapse
CJ Landmark
Medical science monitor 13 (1), RA1-RA7, 2006
2152006
Epilepsy and cannabidiol: a guide to treatment
A Arzimanoglou, U Brandl, JH Cross, A Gil‐Nagel, L Lagae, CJ Landmark, ...
Epileptic Disorders 22 (1), 1-14, 2020
1442020
Antiepileptic drugs in epilepsy and other disorders—a population-based study of prescriptions
CJ Landmark, PG Larsson, E Rytter, SI Johannessen
Epilepsy research 87 (1), 31-39, 2009
1362009
Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population
CJ Landmark, H Fossmark, PG Larsson, E Rytter, SI Johannessen
Epilepsy research 95 (1-2), 51-59, 2011
1352011
Host factors affecting antiepileptic drug delivery—pharmacokinetic variability
CJ Landmark, SI Johannessen, T Tomson
Advanced drug delivery reviews 64 (10), 896-910, 2012
1272012
Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines
A Reimers, JA Berg, ML Burns, E Brodtkorb, SI Johannessen, ...
Drug design, development and therapy, 271-280, 2018
1152018
Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects
C Johannessen Landmark, SI Johannessen, PN Patsalos
Expert opinion on drug metabolism & toxicology 16 (3), 227-238, 2020
1122020
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication
CJ Landmark, A Baftiu, I Tysse, B Valsø, PG Larsson, E Rytter, ...
Therapeutic drug monitoring 34 (4), 440-445, 2012
1032012
Psychiatric comorbidity in patients with epilepsy: a population-based study
M Karouni, S Arulthas, PG Larsson, E Rytter, SI Johannessen, ...
European journal of clinical pharmacology 66, 1151-1160, 2010
1032010
Value of therapeutic drug monitoring in epilepsy
SI Johannessen, CJ Landmark
Expert review of neurotherapeutics 8 (6), 929-939, 2008
1002008
Quantification of the GABA shunt and the importance of the GABA shunt versus the 2‐oxoglutarate dehydrogenase pathway in GABAergic neurons
B Hassel, CU Johannessen, U Sonnewald, F Fonnum
Journal of neurochemistry 71 (4), 1511-1518, 1998
941998
Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring
CJ Landmark, SI Johannessen, T Tomson
Epileptic Disorders 18 (4), 367-383, 2016
902016
Pharmacological management of epilepsy: recent advances and future prospects
CJ Landmark, SI Johannessen
Drugs 68, 1925-1939, 2008
792008
Proconvulsant effects of antidepressants—What is the current evidence?
CJ Landmark, O Henning, SI Johannessen
Epilepsy & Behavior 61, 287-291, 2016
782016
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20